Asset profile
50561
Small molecule
Evidence outlook · lead readout
NCT05811442 · Alzheimer's Disease
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05811442: The study randomized 68 participants to two 50561 dose groups or placebo and masked participants, care providers, investigators, and outcome assessors. Its primary clinical cognitive endpoint was the change in ADAS-Cog 13 at 24 weeks, but no results or statistical comparison were posted, so whether the endpoint was met is unknown.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.